In 2019, China's list of potential unicorn companies was announced, with 48 biopharmaceutical companies on the list

"Pharmaceutical Network Industry Dynamics" potential unicorn enterprises as a reserve army of unicorn enterprises, with development potential and growth, is a pioneer of the new track.
September 3rd, 2020 China's potential unicorn enterprise research report will be held in Nanchang.
Conference, the 2020 China Potential Unicorn Enterprise Research Report (hereinafter referred to as the Report) was successfully unveiled. according to
, GEI China's potential unicorn enterprises through the enterprise self-declaration, open data collection, the Great Wall strategic consulting database screening, third-agency data support, investment institutions and park recommendations and other ways to summarize alternative enterprise data, audit and filter out the standards of China's potential unicorn enterprise groups in 2019, and analyze its development characteristics after the formation.
according to the report, there are 296 potential unicorn enterprises in China in 2019, distributed in commercial aerospace, VR/AR, high-end intelligent equipment, biomedicine and other tracks, mainly concentrated in the "North, Shanghai, Hangzhou, Shenzhen" four cities, and more than half are located in the national high-speed zone.
In the field of biomedicine, according to the author combing, including No cheng Jianhua, Kangfang Biological, Peijia Medical, stone-burning medicine, Ebonod, Pharmaceutical Ming Juno, Hai and Biology, Novzan Bio, Kanga Technology, Olin Bio, Six Heningyuan, Eteng Jingang, Yidi and other at least 48 biopharmaceutical companies on the list.
of the 296 potential unicorn companies, 8 have completed the listing, including Panshengzi, Stone-burning Medicine, Peijia Medical and other biopharmaceutical companies, and a number of listed unicorns focused on the field of oncology.
, Pansheng, a Chinese cancer precision medicine company, successfully completed a public offering on NASDAQ in June, raising $260 million.
company recently disclosed its 2020 Q2 results, the company's total revenue in the second quarter of 2020 was RMB101.7 million, up 40.3% YoY.
of these, revenue from the diagnostic and monitoring business was Rmb93.9m, up 52.1 per cent year-on-year; gross margin rose 85.3 per cent to Rmb64.2m ($9.1m) in the second quarter; and gross margin rose to 63.1 per cent, compared with 47.8 per cent a year earlier.
overall, the company's three key indicators have increased significantly, revenue capacity and efficiency have exceeded market expectations.
In terms of research and development spending, Pansheng's research and development spending in the second quarter reached Rmb29.8m, a significant increase of 55.7 per cent, and the share of research and development spending in revenue increased to 29.3 per cent from 26.4 per cent the previous year.
the financial results revealed that increased investment in innovative products and technology research and development, especially in the field of cancer early screening, is the main factor in the increase in the proportion of investment in research and development of pan-birth children.
and cancer early screening market is recognized by the industry as a bullish blue sea market.
the company's plan, Pansheng will focus its research and development efforts on early screening covering liver, lung and digestive cancer over the next three to five years.
the current pan-birth liver cancer, lung cancer and digestive tract cancer research has been included in the Ministry of Science and Technology of major national special projects, is expected to be in the form of IVD products for registration, the first to achieve market-oriented results transformation.
also went public in the U.S. in June, becoming the first overseas listed company in China's tumor genetic testing industry.
company recently released its second quarter 2020 financial report showing that in the second quarter of 2020, stone-burning medical revenue was RMB174 million, up 26.1% YoY, and a net loss of RMB71.1 million, compared with a loss of RMB26 million a year earlier.
's overall business revenue grew steadily, the hospital market continued to lead the industry, while the layout and increased investment in cancer early detection as the representative of the research and development pipeline.
addition, there are 52 new potential unicorn companies in 2020 (as of July 31), including 10 biopharmaceutical companies such as Tiancheng Pharmaceuticals, Beihai Kangcheng, Soyuan Bio and Mei Berry.